< 1 minute read
Aug. 15, 2021

LNP023: A selective factor B serine protease inhibitor


selective factor B serine protease inhibitor orally available, retinal barrier penetrant J. Med. Chem., Feb. 19, 2020 Novartis (NIBR), Cambridge, MA

Drug Hunter Team

February’s molecule, the Novartis factor B inhibitor LNP023 , targets the serine protease factor B (FB), a key node in the complement system. The complement part of the innate immune system is a hot area for drug discovery due to its increasingly recognized role in a wide range of chronic human diseases, including age-related macular [...]



Other molecules you may be interested in